- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04745845
The Impact of Noradrenaline on Ventriculo-arterial Coupling and Central Cardiovascular Energy Delivery
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
After being informed about the study 40 elective CABG patients with written informed consent will undergo assessment of their arterio-ventricular coupling postoperatively after coronary bypass graft surgery. Whilst still in deep general anesthesia on the CT ICU the study population will be assessed by echocardiographic examination (transthoracic and transesophageal), blood pressure tracing by arterial line, respiratory data and ECG in 4 different situations.
Initially the individual patient is either considered fluid responsive (SVV >13%) og non- responsive (SVV<13%) by using stroke volume variation assessed by echocardiography.
In case of fluid responsiveness a fluid bolus of 4ml/kg of crystalloid fluid is given until SVV drops below 13% and the patient can be considered as fluid NON responder.
Right afterwards the study patient is stabilized with a baseline dose of noradrenaline (NA) intravenously in a supine position (situation 1). Situation 2 will be a slight increase in NA dose stabilizing mean arterial pressure in a "baseline + 20mmHg" state. After reversing the NA dose back to base line level the patient is allowed a short period of rest to wean of drug effect (4-5 x t1/2, appr. 12min). Subsequently the patient is to be placed in a 20% semi upright position (Anti-Trendelenburg) causing an increase in fluid responsiveness (situation 3). Following a phase of equilibration the dose of NA is again titrated up to obtain a 20mmHg increase in mean arterial pressure (situation 4).
There will be logging of arterial pressure curve and VTI-tracing I LVOT simultaneously (ultrapower, uPWR) as well as calculation of energy delivery, cardiac power, oscillatory power and -fraction and both arterial and ventricular elastance in every of those 4 situations.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Trondheim, Norway, 7006
- St Olavs Hospital, Dep. for Anesthesia & Intensive care. Section of cardiothoracic Anesthesia and -intensive Care.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- elective coronary artery bypass graft surgery
- requirement for Noradrenaline/Norepinephrine
Exclusion Criteria:
- lack of informed consent
- patient unsuitable for mean arterial pressure (MAP) elevation of 20mmHg
- patient requiring different blood pressure range due to medical/surgical needs
- poor image quality due to patient factors
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Noradrenalin
treatment with 2 different NA concentrations in 2 different states of fluid responsiveness
|
Norepinephrine challenge (concentration 'A' ) in fluid responsive position
Other Names:
Norepinephrine challenge (concentration 'A') in non-fluid responsive position
Other Names:
Norepinephrine challenge (concentration 'B') in fluid responsive position
Other Names:
Norepinephrine challenge (concentration 'B') in non-fluid responsive position
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Cardiac Power
Time Frame: within 30 minutes after having been stabilised on the cardiothoracic ICU after performed CABG surgery
|
Change in Cardiac Power in reaction to both different noradrenaline doses and states of fluid responsiveness. By logging invasive BP curve and tracing left ventricular outflow tract Velocity Time Integral (by echocardiography) simultaneously Total and Mean Cardiac Power (Watt) can be determined. Examining the response to different NA doses relative to fluid responsiveness the effect of NA on arterio-ventricular coupling can be examined. |
within 30 minutes after having been stabilised on the cardiothoracic ICU after performed CABG surgery
|
Change in Oscillatory Power Fraction
Time Frame: within 30 minutes after having been stabilised on the cardiothoracic ICU after performed CABG surgery
|
Change in Oscillatory Power Fraction (OPF) in reaction to both different noradrenaline doses and states of fluid responsiveness. By logging invasive BP curve and tracing left ventricular outflow tract Velocity Time Integral (by echocardiography) simultaneously Total Cardiac Power (TCP, Watt) and Cardiac Power Output (CPO, Watt) can be determined. By subtracting CPO from TCP, OPF (in %) can be calculated. Examining the response to different NA doses relative to fluid responsiveness the effect of NA on arterio-ventricular coupling can be examined. |
within 30 minutes after having been stabilised on the cardiothoracic ICU after performed CABG surgery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in single beat ventricular elastance
Time Frame: within 30 minutes after having been stabilised on the cardiothoracic ICU after performed CABG surgery
|
Change in single beat ventricular elastance in reaction to both different noradrenaline doses and states of fluid responsiveness. Ventricular elastance (Ees) can be determined on the bedside by using a single beat measurement of left ventricular ejection fraction, stroke volume, preejection time and ejection time. |
within 30 minutes after having been stabilised on the cardiothoracic ICU after performed CABG surgery
|
Change in single beat arterial elastance
Time Frame: within 30 minutes after having been stabilised on the cardiothoracic ICU after performed CABG surgery
|
Change in single beat arterial elastance in reaction to both different noradrenaline doses and states of fluid responsiveness.
Using an estimative formula Ea can be calculated (Ea=SBPx0.9/SV)
and Ea/Ees as a marker of arterio-ventricular coupling can be evaluated.
|
within 30 minutes after having been stabilised on the cardiothoracic ICU after performed CABG surgery
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Hilde Pleym (Head of Department), md, PhD, St. Olavs Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Heart Diseases
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Adrenergic alpha-Agonists
- Adrenergic Agonists
- Sympathomimetics
- Vasoconstrictor Agents
- Norepinephrine
Other Study ID Numbers
- 2019/287
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heart Diseases
-
Baker Heart and Diabetes InstitutePrincess Alexandra Hospital, Brisbane, Australia; Royal Perth Hospital; Alice... and other collaboratorsRecruitingHeart Failure | Valve Heart DiseaseAustralia
-
Medical University of ViennaUnknownHeart Diseases | Heart Failure | Valvular Heart DiseaseAustria
-
Centre Chirurgical Marie LannelongueActive, not recruitingValvular Heart Disease | Valve Disease, Heart
-
Abiomed Inc.RecruitingHeart Diseases | Acute Decompensated Heart Failure | Congestive Heart Failure | Acute Heart FailureUnited States
-
Wuerzburg University HospitalRecruitingHeart Failure | Chronic Heart Failure | Chronic Heart DiseaseGermany
-
Kathirvel SubramaniamUniversity of Maryland, Baltimore; CSL BehringRecruitingHeart Failure,Congestive | Heart Disease End StageUnited States
-
University of MichiganTerminatedDiastolic Heart Failure | Hypertensive Heart DiseaseUnited States
-
University College, LondonBritish Heart Foundation; Horizon 2020 - European CommissionRecruitingValvular Heart DiseaseUnited Kingdom
-
Cairo UniversityRecruitingHeart Diseases | Heart Valve Diseases | Open Heart SurgeryEgypt
-
Sheba Medical CenterRecruitingCardiovascular Diseases | Valvular Heart DiseaseIsrael
Clinical Trials on Noradrenalin
-
University of Turin, ItalyCompleted
-
University Hospital FreiburgUniversity Hospital Muenster; Johannes Gutenberg University Mainz; Jena University...Not yet recruitingLiver Cirrhosis | Chronic Kidney Diseases | Hepato-Renal Syndrome
-
Sahlgrenska University Hospital, SwedenUnknownHeart Failure, Right-Sided | Heart Failure, Left-SidedSweden
-
Suez Canal UniversityCompletedHyperthermic Intraperitoneal Chemotherapy (HIPEC)Egypt
-
University of AarhusRecruiting
-
Ankara UniversityCompletedHypotension | Cesarean Section | Anesthesia, SpinalTurkey
-
Helse FonnaRecruitingAnesthesia, General | Anesthesia, Intravenous | Hemodynamic InstabilityNorway